APVO — Aptevo Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1671584 ·
Last close
$1.91
Market Cap
$3.46M
52W High
$35.64
52W Low
$1.37
ADV30
161,560
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,443,000 | -6,356,000 | 14,519,000 | 9,797,000 | 8,478,000 |
| Mar 2026 | 0 | — | -6,837,000 | -6,697,000 | 19,902,000 | 14,524,000 | 8,290,000 |
| Dec 2025 | 0 | — | -5,996,000 | -5,806,000 | 27,194,000 | 21,619,000 | 9,813,000 |
| Sep 2025 | 0 | — | -7,610,000 | -7,549,000 | 26,996,000 | 21,061,000 | 9,604,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-26,982,000
Investing CF
$0
Financing CF
$39,368,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1779.56
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-281,909,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-26,669,000
Pretax Income TTM
$-26,256,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,312,000 | -25,967,000 | 27,194,000 | 9,813,000 | 17,381,000 | -25,592,000 |
| Dec 2024 | 0 | -24,602,000 | -24,130,000 | 15,591,000 | 10,836,000 | 4,755,000 | -23,785,000 |
| Dec 2023 | 0 | -28,878,000 | -17,411,000 | 24,842,000 | 12,621,000 | 12,221,000 | -11,730,000 |
| Dec 2022 | 3,114,000 | -28,641,000 | 8,027,000 | 34,215,000 | 16,241,000 | 17,974,000 | -21,022,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-10.40
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| REVB | REVELATION BIOSCIENCES, INC. | $3.42M | $0.86 | — |
| MBIO | MUSTANG BIO, INC. | $3.41M | $0.51 | — |
| PRFX | PRF Technologies Ltd. | $3.40M | $0.97 | — |
| ADXN | Addex Therapeutics Ltd. | $3.56M | $2.81 | — |
| HCWB | HCW Biologics Inc. | $3.34M | $1.82 | — |
News headlines (Yahoo Finance, 1h cache)
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
2026-09-24 12:05 · Yahoo
Aptevo Reports 93% Clinical Benefit Rate for Mipletamig Triplet in TP53-Mutated AML
2026-09-03 14:19 · Yahoo
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
2026-09-03 12:05 · Yahoo
APVO: Focusing on Three Key Areas of Development
2026-08-24 09:02 · Yahoo
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
2026-08-14 12:05 · Yahoo
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
2026-08-12 13:30 · Yahoo
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
2026-07-27 12:05 · Yahoo
Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
2026-06-30 12:05 · Yahoo
APVO: Initiating Coverage of Aptevo Therapeutics Inc.; Unlocking the Next Generation of Multispecific Immune Engagement
2026-06-16 09:15 · Yahoo
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
2026-05-28 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.